Add BrightSurf on Google Email

Journal of the National Cancer Institute


Other highlights in the April 4 JNCI

Testicular cancer survivors have a higher risk of dying from noncancer causes, including infections and circulatory diseases. Chemotherapy treatment in the 1970s also increases this risk. Researchers highlight the need for additional long-term follow-up studies to better understand secondary complications.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateApr 3, 2007

Radiation preferred over surgery for patients with some stages of lung cancer

According to a randomized controlled trial, radiation therapy is the preferred treatment option for patients with locally advanced stage IIIA-N2 non-small-cell lung cancer who have responded to chemotherapy. This finding suggests that surgery may not improve survival rates compared to radiation after chemotherapy treatment.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateMar 20, 2007

Lung cancer risk reduced in female textile workers exposed to endotoxin

A new study published in the Journal of the National Cancer Institute found that female Chinese textile workers with high-level exposure to bacterial endotoxin have a 40% decreased risk of developing lung cancer. The researchers also noted that the protective effect was strongest for women exposed early in their career.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateMar 6, 2007

Other highlights in the March 7 JNCI

Researchers found that changes in breast density over time can predict a woman's risk of breast cancer, with higher densities linked to greater risks. Meanwhile, targeting prostate-specific proteins may lead to effective treatments for prostate cancer and other diseases, leaving non-prostate cells unharmed.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateMar 6, 2007

Other highlights in the Feb. 21 JNCI

A new screening protocol has been identified that can detect Lynch syndrome, a disorder that increases the risk of developing colorectal cancer at a young age. The screening procedure detected mutations in 69 patients and identified at least 57 HNPCC patients who would not have been screened under current testing practices.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateFeb 20, 2007

Growth factors given with chemotherapy associated with increased risk of blood diseases

A study published in the Journal of the National Cancer Institute found that women with breast cancer who received growth factors during chemotherapy had a higher risk of developing leukemia or myelodysplastic syndrome. The absolute risk is small, but it should be considered when making treatment decisions.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateFeb 6, 2007

Other highlights in the February 7 JNCI

A new study found that hairy cell leukemia survivors have an increased risk of developing certain cancers, including Hodgkin lymphoma and thyroid cancer. Meanwhile, a new test may be able to identify patients with a specific type of gene mutation that indicates an inherited form of colorectal cancer or potential response to certain drugs.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateFeb 6, 2007

No benefit to increasing dose intensity of chemotherapy in osteosarcoma, study finds

A randomized trial found that increasing chemotherapy dose intensity did not improve survival rates in patients with osteosarcoma. However, the dose-intensive regimen showed better tumor cell death and lower risks of certain side effects. The study challenges the use of histologic response as a key predictor factor for treatment outcomes.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateJan 16, 2007

Other highlights in the January 3 JNCI

Recent research suggests that regular statin use is not linked to lower colorectal cancer risk, while folate intake does not appear to impact breast cancer risk. However, monitoring of thyroid function may be necessary for patients taking the medication sunitinib, which can cause fatigue and hypothyroidism.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateJan 2, 2007

Other highlights in the Dec. 6 JNCI

A new Italian risk model was found to be as accurate as a commonly used US model in predicting breast cancer diagnosis, suggesting the possibility of revising the model to include additional risk factors. Additionally, genetic variants have been linked to diarrhea when treated with certain cancer drugs, including gefitinib.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateDec 5, 2006

Quality care assessment examines surgical quality for colorectal cancer patients

Researchers identified 142 candidate indicators of quality care for colorectal cancer surgery, including surgical credentials, preoperative evaluation, and postoperative management. The expert panel rated 92 indicators as valid, suggesting these can be used to measure care quality and create improvement programs.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateNov 14, 2006

Other highlights in the September 6 JNCI

A 55-gene expression profile identifies children at high risk of progressive metastatic neuroblastoma. Lay health advisors improve mammography use among low-income women. Cyclin D1 inhibits STAT3, slowing breast cancer tumor growth. Researchers identify CD95/CD95L as a molecular system involved in radiation-induced pneumonitis.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateSep 5, 2006

Gene signature assesses breast cancer outcomes

A new gene signature of 70 genes linked to breast cancer was found to accurately predict patient outcomes, surpassing traditional risk classifiers. The study's results suggest that the 70-gene signature adds valuable prognostic information, which may lead to improved treatment decisions and reduced chemotherapy for eligible patients.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateSep 5, 2006